AI assistant
IMPEDIMED LIMITED — Call Transcript 2023
Aug 15, 2023
65135_rns_2023-08-15_30012fce-938e-468b-90d4-62b51f5b6da5.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [230 x 54] intentionally omitted <==
16 August 2023
ASX ANNOUNCEMENT
Conference Call with ImpediMed Directors
ImpediMed Limited ( ImpediMed or the Company ) (ASX:IPD) advises that its Directors will be holding a shareholder conference call at 9:30am AEST (Sydney/Melbourne) on Thursday, 17 August 2023.
The live call and Q&A will be hosted by ImpediMed’s Chair, Don Williams and will be joined by the Board of Directors as well as CEO, Rick Valencia and CFO, Tim Cruickshank.
To pre-register, please follow this link:
https://us02web.zoom.us/webinar/register/WN_e8qK3KzqSlqpcv9gOQdNNA
Investors are encouraged to send questions in advance to Hannah Howlett at [email protected].
Approved for release by the Managing Director and CEO, Mr Rick Valencia.
Contact Details
Investor relations Contact:
Hannah Howlett WE Communications T: +61 (0) 4 5064 8064 E: [email protected]
About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO[®] Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.
In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines[®] ) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex[®] , ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed’s SaaS subscription-based business.
For more information, visit www.impedimed.com.